Literature DB >> 35418692

Matriptase-2/NR4A3 axis switches TGF-β action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis.

Hsin-Ying Lin1, Chun-Jung Ko1, Tzu-Yu Lo1, Shang-Ru Wu1, Shao-Wei Lan1, Chen-An Huang1, Yi-Chin Lin1, Hsin-Hsien Lin1, Hsin-Fang Tu1, Cheng-Fan Lee1, Pei-Wen Hsiao2, Hsiang-Po Huang3, Mei-Jou Chen4, Kai-Hsiung Chang5, Ming-Shyue Lee6.   

Abstract

Dysregulation of pericellular proteolysis is strongly implicated in cancer metastasis through alteration of cell invasion and the microenvironment. Matriptase-2 (MT-2) is a membrane-anchored serine protease which can suppress prostate cancer (PCa) cell invasion. In this study, we showed that MT-2 was down-regulated in PCa and could suppress PCa cell motility, tumor growth, and metastasis. Using microarray and biochemical analysis, we found that MT-2 shifted TGF-β action towards its tumor suppressor function by repressing epithelial-to-mesenchymal transition (EMT) and promoting Smad2 phosphorylation and nuclear accumulation to upregulate two TGF-β1 downstream effectors (p21 and PAI-1), culminating in hindrance of PCa cell motility and malignant growth. Mechanistically, MT-2 could dramatically up-regulate the expression of nuclear receptor NR4A3 via iron metabolism in PCa cells. MT-2-induced NR4A3 further coactivated Smad2 to activate p21 and PAI-1 expression. In addition, NR4A3 functioned as a suppressor of PCa and mediated MT-2 signaling to inhibit PCa tumorigenesis and metastasis. These results together indicate that NR4A3 sustains MT-2 signaling to suppress PCa cell invasion, tumor growth, and metastasis, and serves as a contextual factor for the TGF-β/Smad2 signaling pathway in favor of tumor suppression via promoting p21 and PAI-1 expression.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35418692     DOI: 10.1038/s41388-022-02303-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression.

Authors:  Jodie L Babitt; Franklin W Huang; Diedra M Wrighting; Yin Xia; Yisrael Sidis; Tarek A Samad; Jason A Campagna; Raymond T Chung; Alan L Schneyer; Clifford J Woolf; Nancy C Andrews; Herbert Y Lin
Journal:  Nat Genet       Date:  2006-04-09       Impact factor: 38.330

Review 2.  The type II transmembrane serine protease matriptase-2--identification, structural features, enzymology, expression pattern and potential roles.

Authors:  Andrew J Ramsay; Janet C Reid; Gloria Velasco; James P Quigley; John D Hooper
Journal:  Front Biosci       Date:  2008-01-01

Review 3.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 4.  Emerging roles of proteases in tumour suppression.

Authors:  Carlos López-Otín; Lynn M Matrisian
Journal:  Nat Rev Cancer       Date:  2007-10       Impact factor: 60.716

5.  Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis.

Authors:  Alicia R Folgueras; Fernando Martín de Lara; Alberto M Pendás; Cecilia Garabaya; Francisco Rodríguez; Aurora Astudillo; Teresa Bernal; Rubén Cabanillas; Carlos López-Otín; Gloria Velasco
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

Review 6.  Pericellular proteolysis in cancer.

Authors:  Lisa Sevenich; Johanna A Joyce
Journal:  Genes Dev       Date:  2014-11-01       Impact factor: 11.361

7.  The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin.

Authors:  Laura Silvestri; Alessia Pagani; Antonella Nai; Ivana De Domenico; Jerry Kaplan; Clara Camaschella
Journal:  Cell Metab       Date:  2008-10-30       Impact factor: 27.287

8.  Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.

Authors:  Christian Parr; Andrew J Sanders; Gaynor Davies; Tracey Martin; Jane Lane; Malcolm D Mason; Robert E Mansel; Wen G Jiang
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

Review 9.  Genetics and biology of prostate cancer.

Authors:  Guocan Wang; Di Zhao; Denise J Spring; Ronald A DePinho
Journal:  Genes Dev       Date:  2018-09-01       Impact factor: 11.361

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.